The Lead Episode 20: A Discussion of (RAPID): A Multicentre, Randomised Trial

Description

Etripamil is a fast-acting, intranasally administered calcium-channel blocker in development for ondemand therapy outside a health-care setting for paroxysmal supraventricular tachycardia. The authors of this randomized trial evaluated the efficacy and safety of etripamil 70 mg nasal spray using a symptom-prompted, repeat-dose regimen for acute conversion of atrioventricular-nodal-dependent paroxysmal supraventricular tachycardia to sinus rhythm within 30 min.

Learning Objectives

To understand the findings of the recently published clinical study entitled, "Self-administered intranasal etripamil using a symptomprompted, repeat-dose regimen for atrioventricular-nodal dependent supraventricular tachycardia (RAPID): a multicentre, randomized trial."

Article Authors and Podcast Contributors

Article Authors
Bruce S Stambler, A John Camm, Marco Alings, Paul Dorian, Hein Heidbuchel, Jaco Houtgraaf, Peter R Kowey, Jose L Merino, Blandine Mondésert, Jonathan P Piccini, Sean D Pokorney, Philip T Sager, Atul Verma, J Marcus Wharton, David B Bharucha, Francis Plat, Silvia Shardonofsky, Michael Chen, James E Ip, on behalf of the RAPID Investigators

Podcast Contributors
William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital
David Chiang, MD, PhD, of Brigham and Women’s Hospital
Sunil Kapur MD, of Brigham and Women's Hospital

Disclosures

All relevant financial relationships have been mitigated.

Host Disclosure(s):
W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic

Contributor Disclosure(s):
D. Chiang: No relevant financial relationships with ineligible companies to disclose.
S. Kapur: Honoraria/Speaking/Consulting Fee: Biotronik, Abbott, Medtronic, Inc, Novartis

Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
J. Glenn: No relevant financial relationships with ineligible companies to disclose.
S. Sailor: No relevant financial relationships with ineligible companies to disclose.

Summary


Availability:	On-Demand


Cost:	FREE


Credit Offered:	No Credit Offered

Recommended

The Lead Episode 68: Ischemia-induced ventricular proarrhythmia and cardiovascular autonomic dysreflexia after cardioneuroablation

Multiple Credits

FREE

Heart Rhythm 2024 On Demand - Late Breaking Clinical Trials

Multiple Credits

$99.00 - $199.00

(1)

Heart Rhythm 2024 On Demand - Cardiac Implantable Electronic Devices

Multiple Credits

$249.00 - $349.00

(4)

Heart Rhythm 2024 On Demand - Ablation

Multiple Credits

$249.00 - $349.00

Heart Rhythm 2024 On Demand – Various Sessions

Multiple Credits

$249.00 - $349.00

(1)

The Lead Episode 65: QRS Morphology and the Risk of Ventricular Tachyarrhythmia in Cardiac Resynchronization Therapy Recipients

Multiple Credits

FREE

The Lead Episode 63: Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial

Multiple Credits

FREE

(1)

The Lead Episode 55: Dynamic Electrocardiogram changes are a novel risk marker for sudden Cardiac Death

Multiple Credits

FREE

Core Concepts in Remote Monitoring 2023 Module 1: The Current State of Remote Monitoring in EP

Multiple Credits

$99.00 - $125.00

(7)